
Title:
WHO Model List of Essential Medicines
Text:
Formulary



.mw-parser-output .hatnote{font-style:italic}.mw-parser-output div.hatnote{padding-left:1.6em;margin-bottom:0.5em}.mw-parser-output .hatnote i{font-style:normal}.mw-parser-output .hatnote+link+.hatnote{margin-top:-0.5em}For the list for children, see WHO Model List of Essential Medicines for Children.
  2017 marked the 40th anniversary of the WHO Model List of Essential Medicines.
The WHO Model List of Essential Medicines (aka Essential Medicines List or EML[1]), published by the World Health Organization (WHO), contains the medications considered to be most effective and safe to meet the most important needs in a health system.[2] The list is frequently used by countries to help develop their own local lists of essential medicines.[2] As of 2016[update], more than 155 countries have created national lists of essential medicines based on the World Health Organization's model list.[1] This includes countries in both the developed and developing world.[2][3]
The list is divided into core items and complementary items.[4] The core items are deemed to be the most cost-effective options for key health problems and are usable with little additional health care resources.[4] The complementary items either require additional infrastructure such as specially trained health care providers or diagnostic equipment or have a lower cost–benefit ratio.[4] About 25% of items are in the complementary list.[5] Some medications are listed as both core and complementary.[6] While most medications on the list are available as generic products, being under patent does not preclude inclusion.[7]
The first list was published in 1977 and included 208 medications.[8][2][9] The WHO updates the list every two years.[10] The 14th list was published in 2005 and contained 306 medications.[11] In 2015, the 19th edition of the list was published and contains around 410 medications.[10] The 20th edition was published in 2017, and contains 433 medications.[12][13] The 21st list was published in 2019 and contains 460 medications.[14][15][16] The 22nd list was published in 2021 and contains 479 medications.[17][18] Various national lists contain between 334 and 580 medications.[5]
A separate list for children up to 12 years of age, known as the WHO Model List of Essential Medicines for Children (EMLc), was created in 2007 and is in its 8th edition.[10][19][20] It was created to make sure that the needs of children were systematically considered such as availability of proper formulations.[21][22] Everything in the children's list is also included in the main list.[23] The list and notes are based on the 19th to 22nd edition of the main list.[4][12][14][17] An α indicates a medicine is only on the complementary list.[4][14][17] Therapeutic alternatives with similar clinical performance are listed for some medicines and they may be considered for national essential medicines lists.[17][18]

.mw-parser-output .toclimit-2 .toclevel-1 ul,.mw-parser-output .toclimit-3 .toclevel-2 ul,.mw-parser-output .toclimit-4 .toclevel-3 ul,.mw-parser-output .toclimit-5 .toclevel-4 ul,.mw-parser-output .toclimit-6 .toclevel-5 ul,.mw-parser-output .toclimit-7 .toclevel-6 ul{display:none}Contents

1 Anaesthetics, preoperative medicines and medical gases

1.1 General anaesthetics and oxygen

1.1.1 Inhalational medicines
1.1.2 Injectable medicines


1.2 Local anaesthetics
1.3 Preoperative medication and sedation for short-term procedures
1.4 Medical gases


2 Medicines for pain and palliative care

2.1 Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
2.2 Opioid analgesics
2.3 Medicines for other common symptoms in palliative care


3 Antiallergics and medicines used in anaphylaxis
4 Antidotes and other substances used in poisonings

4.1 Non-specific
4.2 Specific


5 Anticonvulsants/antiepileptics
6 Anti-infective medicines

6.1 Anthelminthics

6.1.1 Intestinal anthelminthics
6.1.2 Antifilarials
6.1.3 Antischistosomals and other antinematode medicines
6.1.4 Cysticidal medicines


6.2 Antibacterials

6.2.1 Access group antibiotics
6.2.2 Watch group antibiotics
6.2.3 Reserve group antibiotics
6.2.4 Antileprosy medicines
6.2.5 Antituberculosis medicines


6.3 Antifungal medicines
6.4 Antiviral medicines

6.4.1 Antiherpes medicines
6.4.2 Antiretrovirals

6.4.2.1 Nucleoside/nucleotide reverse transcriptase inhibitors
6.4.2.2 Non-nucleoside reverse transcriptase inhibitors
6.4.2.3 Protease inhibitors
6.4.2.4 Integrase inhibitors
6.4.2.5 Fixed-dose combinations of antiretroviral medicines
6.4.2.6 Medicines for prevention of HIV-related opportunistic infections
6.4.2.7 Other antivirals


6.4.3 Antihepatitis medicines

6.4.3.1 Medicines for hepatitis B

6.4.3.1.1 Nucleoside/Nucleotide reverse transcriptase inhibitors


6.4.3.2 Medicines for hepatitis C

6.4.3.2.1 Pangenotypic direct-acting antiviral combinations
6.4.3.2.2 Non-pangenotypic direct-acting antiviral combinations
6.4.3.2.3 Other antivirals for hepatitis C






6.5 Antiprotozoal medicines

6.5.1 Antiamoebic and antigiardiasis medicines
6.5.2 Antileishmaniasis medicines
6.5.3 Antimalarial medicines

6.5.3.1 For curative treatment
6.5.3.2 For chemoprevention


6.5.4 Antipneumocystosis and antitoxoplasmosis medicines
6.5.5 Antitrypanosomal medicines

6.5.5.1 African trypanosomiasis

6.5.5.1.1 Medicines for the treatment of 1st stage African trypanosomiasis
6.5.5.1.2 Medicines for the treatment of 2nd stage African trypanosomiasis


6.5.5.2 American trypanosomiasis




6.6 Medicines for ectoparasitic infections


7 Antimigraine medicines

7.1 For treatment of acute attack
7.2 For prophylaxis


8 Immunomodulators and antineoplastics

8.1 Immunomodulators for non-malignant disease
8.2 Antineoplastics and supportive medicines

8.2.1 Cytotoxic medicines
8.2.2 Targeted therapies
8.2.3 Immunomodulators
8.2.4 Hormones and antihormones
8.2.5 Supportive medicines




9 Antiparkinsonism medicines
10 Medicines affecting the blood

10.1 Antianaemia medicines
10.2 Medicines affecting coagulation
10.3 Other medicines for haemoglobinopathies


11 Blood products of human origin and plasma substitutes

11.1 Blood and blood components
11.2 Plasma-derived medicines

11.2.1 Human immunoglobulins
11.2.2 Blood coagulation factors


11.3 Plasma substitutes


12 Cardiovascular medicines

12.1 Antianginal medicines
12.2 Antiarrhythmic medicines
12.3 Antihypertensive medicines
12.4 Medicines used in heart failure
12.5 Antithrombotic medicines

12.5.1 Anti-platelet medicines
12.5.2 Thrombolytic medicines


12.6 Lipid-lowering agents


13 Dermatological medicines (topical)

13.1 Antifungal medicines
13.2 Anti-infective medicines
13.3 Anti-inflammatory and antipruritic medicines
13.4 Medicines affecting skin differentiation and proliferation
13.5 Scabicides and pediculicides


14 Diagnostic agents

14.1 Ophthalmic medicines
14.2 Radiocontrast media


15 Antiseptics and disinfectants

15.1 Antiseptics
15.2 Disinfectants


16 Diuretics
17 Gastrointestinal medicines

17.1 Antiulcer medicines
17.2 Antiemetic medicines
17.3 Anti-inflammatory medicines
17.4 Laxatives
17.5 Medicines used in diarrhoea

17.5.1 Oral rehydration
17.5.2 Medicines for diarrhea




18 Medicines for endocrine disorders

18.1 Adrenal hormones and synthetic substitutes
18.2 Androgens
18.3 Estrogens
18.4 Progestogens
18.5 Medicines for diabetes

18.5.1 Insulins
18.5.2 Oral hypoglycaemic agents
18.5.3 Medicines for hypoglycaemia


18.6 Thyroid hormones and antithyroid medicines


19 Immunologicals

19.1 Diagnostic agents
19.2 Sera, immunoglobulins and monoclonal antibodies
19.3 Vaccines


20 Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
21 Ophthalmological preparations

21.1 Anti-infective agents
21.2 Anti-inflammatory agents
21.3 Local anesthetics
21.4 Miotics and antiglaucoma medicines
21.5 Mydriatics
21.6 Anti-vascular endothelial growth factor (VEGF)


22 Medicines for reproductive health and perinatal care

22.1 Contraceptives

22.1.1 Oral hormonal contraceptives
22.1.2 Injectable hormonal contraceptives
22.1.3 Intrauterine devices
22.1.4 Barrier methods
22.1.5 Implantable contraceptives
22.1.6 Intravaginal contraceptives


22.2 Ovulation inducers
22.3 Uterotonics
22.4 Antioxytocics (tocolytics)
22.5 Medicines administered to the mother
22.6 Medicines administered to the neonate


23 Peritoneal dialysis solution
24 Medicines for mental and behavioural disorders

24.1 Medicines used in psychotic disorders
24.2 Medicines used in mood disorders

24.2.1 Medicines used in depressive disorders
24.2.2 Medicines used in bipolar disorders


24.3 Medicines for anxiety disorders
24.4 Medicines used for obsessive compulsive disorders
24.5 Medicines for disorders due to psychoactive substance use


25 Medicines acting on the respiratory tract

25.1 Antiasthmatics and medicines for chronic obstructive pulmonary disease


26 Solutions correcting water, electrolyte and acid-base disturbances

26.1 Oral
26.2 Parenteral
26.3 Miscellaneous


27 Vitamins and minerals
28 Ear, nose and throat medicines
29 Medicines for diseases of joints

29.1 Medicines used to treat gout
29.2 Disease-modifying agents used in rheumatoid disorders (DMARDs)
29.3 Juvenile joint diseases
29.4 Dental preparations


30 Notes
31 References
32 Further reading
33 External links



Anaesthetics, preoperative medicines and medical gases[edit]
General anaesthetics and oxygen[edit]
Inhalational medicines[edit]
Halothane
Isoflurane
Nitrous oxide
Oxygen
Injectable medicines[edit]
Ketamine
Propofol[note 1]
Local anaesthetics[edit]
Bupivacaine
Lidocaine
Lidocaine/epinephrine (lidocaine + epinephrine)
Ephedrineα[note 2]
Preoperative medication and sedation for short-term procedures[edit]
Atropine
Midazolam
Morphine
Medical gases[edit]
Oxygen[note 3]
Medicines for pain and palliative care[edit]
Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)[edit]
  A skeletal model of the chemical structure of aspirin
Acetylsalicylic acid (aspirin)
Ibuprofen[note 4]
Paracetamol[note 5] (acetaminophen)
Opioid analgesics[edit]
Codeine
Fentanyl[note 6]
Morphine[note 7]
Methadoneα[note 8]
Medicines for other common symptoms in palliative care[edit]
Amitriptyline
Cyclizine
Dexamethasone
Diazepam
Docusate sodium
Fluoxetine
Haloperidol
Hyoscine butylbromide
Hyoscine hydrobromide
Lactulose
Loperamide
Metoclopramide
Midazolam
Ondansetron[note 9]
Senna
Antiallergics and medicines used in anaphylaxis[edit]
Dexamethasone
Epinephrine (adrenaline)
Hydrocortisone
Loratadine[note 10][note 11]
Prednisolone[note 12]
Antidotes and other substances used in poisonings[edit]
Non-specific[edit]
Charcoal, activated
Specific[edit]
Acetylcysteine
Atropine
Calcium gluconate
Methylthioninium chloride (methylene blue)
Naloxone
Penicillamine
Prussian blue
Sodium nitrite
Sodium thiosulfate
Deferoxamineα
Dimercaprolα
Fomepizoleα
Sodium calcium edetateα
Succimerα
Anticonvulsants/antiepileptics[edit]
Carbamazepine
Diazepam
Lamotrigine[note 13]
Lorazepam[note 14]
Magnesium sulfate[note 15]
Midazolam[note 16]
Phenobarbital
Phenytoin[note 17]
Valproic acid (sodium valproate)[note 18]
Ethosuximideα
Valproic acid (sodium valproate)α
Anti-infective medicines[edit]
Anthelminthics[edit]
Intestinal anthelminthics[edit]
  A skeletal model of the chemical structure of albendazole
Albendazole
Ivermectin
Levamisole
Mebendazole
Niclosamide
Praziquantel
Pyrantel
Antifilarials[edit]
Albendazole
Diethylcarbamazine
Ivermectin
Antischistosomals and other antinematode medicines[edit]
Praziquantel
Triclabendazole
Oxamniquineα[note 19]
Cysticidal medicines[edit]
Albendazoleα
Mebendazoleα
Praziquantelα
Antibacterials[edit]
Access group antibiotics[edit]
Amikacin
Amoxicillin
Amoxicillin/clavulanic acid (amoxicillin + clavulanic acid)
Ampicillin
Benzathine benzylpenicillin
Benzylpenicillin
Cefalexin
Cefazolin[note 20]
Chloramphenicol[note 21]
Clindamycin
Cloxacillin[note 22][note 23]
Doxycycline[note 24]
Gentamicin
Metronidazole
Nitrofurantoin
Phenoxymethylpenicillin (penicillin V)
Procaine benzylpenicillin[note 25]
Spectinomycin
Sulfamethoxazole/trimethoprim (sulfamethoxazole + trimethoprim)
Trimethoprim
Watch group antibiotics[edit]
Azithromycin
Cefixime
Cefotaxime[note 26]
Ceftriaxone[note 27][note 28]
Cefuroxime
Ciprofloxacin
Clarithromycin[note 29]
Piperacillin/tazobactam (piperacillin + tazobactam)
Vancomycin
Ceftazidimeα
Meropenemα[note 30]
Vancomycinα
Reserve group antibiotics[edit]
Cefiderocolα
Ceftazidime/avibactam (ceftazidime + avibactam)α
Colistinα
Fosfomycinα
Linezolidα
Meropenem/vaborbactam (meropenem + vaborbactam)α
Plazomicinα
Polymyxin Bα
Antileprosy medicines[edit]
Clofazimine
Dapsone
Rifampicin
Antituberculosis medicines[edit]
  Pure crystals of ethambutol
Ethambutol
Ethambutol/isoniazid/pyrazinamide/rifampicin (ethambutol + isoniazid + pyrazinamide + rifampicin)
Ethambutol/isoniazid/rifampicin (ethambutol + isoniazid + rifampicin)
Isoniazid
Isoniazid/pyrazinamide/rifampicin (isoniazid + pyrazinamide + rifampicin)
Isoniazid/rifampicin (isoniazid + rifampicin)
Isoniazid/rifapentine (isoniazid + rifapentine)
Moxifloxacin
Pyrazinamide
Rifabutin[note 31]
Rifampicin
Rifapentine
Amikacinα
Amoxicillin/clavulanic acid (amoxicillin + clavulanic acid)α[note 32]
Bedaquilineα[note 33]
Clofazimineα
Cycloserineα[note 34]
Delamanidα
Ethionamideα[note 35]
Levofloxacinα
Linezolidα
Meropenemα[note 36]
Moxifloxacinα
P-aminosalicylic acidα
Streptomycinα
Antifungal medicines[edit]
Amphotericin B
Clotrimazole
Fluconazole
Flucytosine
Griseofulvin
Itraconazole[note 37]
Nystatin
Voriconazole[note 38]
Micafunginα[note 39]
Potassium iodideα
Antiviral medicines[edit]
Antiherpes medicines[edit]
Aciclovir[note 40]
Antiretrovirals[edit]
Nucleoside/nucleotide reverse transcriptase inhibitors[edit]
Abacavir
Lamivudine
Tenofovir disoproxil fumarate[note 41]
Zidovudine
Non-nucleoside reverse transcriptase inhibitors[edit]
Efavirenz
Nevirapine
Protease inhibitors[edit]
  Two capsules of atazanavir
Atazanavir/ritonavir (atazanavir + ritonavir)
Darunavir
Lopinavir/ritonavir (lopinavir + ritonavir)
Ritonavir
Integrase inhibitors[edit]
Dolutegravir
Raltegravir[note 42]
Fixed-dose combinations of antiretroviral medicines[edit]
Abacavir/lamivudine (abacavir + lamivudine)
Dolutegravir/lamivudine/tenofovir (dolutegravir + lamivudine + tenofovir
Efavirenz/emtricitabine/tenofovir[note 43]
Efavirenz/lamivudine/tenofovir (efavirenz + lamivudine + tenofovir)
Emtricitabine/tenofovir (emtricitabine + tenofovir)[note 43][note 44]
Lamivudine/zidovudine (lamivudine + zidovudine)
Medicines for prevention of HIV-related opportunistic infections[edit]
Isoniazid/pyridoxine/sulfamethoxazole/trimethoprim (isoniazid + pyridoxine + sulfamethoxazole + trimethoprim)
Other antivirals[edit]
Ribavirin[note 45]
Valganciclovir[note 46]
Oseltamivirα[note 47]
Valganciclovirα[note 48]
Antihepatitis medicines[edit]
Medicines for hepatitis B[edit]
Nucleoside/Nucleotide reverse transcriptase inhibitors[edit]
Entecavir
Tenofovir disoproxil fumarate
Medicines for hepatitis C[edit]
Pangenotypic direct-acting antiviral combinations[edit]
Daclatasvir[note 49]
Daclatasvir/sofosbuvir (daclatasvir + sofosbuvir)
Glecaprevir/pibrentasvir (glecaprevir + pibrentasvir)
Sofosbuvir[note 50]
Sofosbuvir/velpatasvir (sofosbuvir + velpatasvir)
Non-pangenotypic direct-acting antiviral combinations[edit]
Dasabuvir
Ledipasvir/sofosbuvir (ledipasvir + sofosbuvir)
Ombitasvir/paritaprevir/ritonavir (ombitasvir + paritaprevir + ritonavir)
Other antivirals for hepatitis C[edit]
Ribavirin[note 51]
Pegylated interferon-alpha-2a or pegylated interferon-alpha-2bα[note 52]
Antiprotozoal medicines[edit]
Antiamoebic and antigiardiasis medicines[edit]
Diloxanide
Metronidazole[note 53]
Antileishmaniasis medicines[edit]
Amphotericin B
Miltefosine
Paromomycin
Sodium stibogluconate or meglumine antimoniate
Antimalarial medicines[edit]
For curative treatment[edit]
Amodiaquine[note 54]
Artemether[note 55]
Artemether/lumefantrine (artemether + lumefantrine)[note 56]
Artesunate[note 57]
Artesunate/amodiaquine (artesunate + amodiaquine)[note 58]
Artesunate/mefloquine (artesunate + mefloquine)
Artesunate/pyronaridine tetraphosphate (artesunate + pyronaridine tetraphosphate)
Chloroquine[note 59]
Dihydroartemisinin/piperaquine phosphate (dihydroartemisinin + piperaquine phosphate)
Doxycycline[note 60]
Mefloquine[note 54]
Primaquine[note 61]
Quinine[note 62]
Sulfadoxine/pyrimethamine (sulfadoxine + pyrimethamine)[note 63]
For chemoprevention[edit]
Amodiaquine + sulfadoxine/pyrimethamine (Co-packaged)
Chloroquine[note 64]
Doxycycline
Mefloquine
Proguanil[note 65]
Sulfadoxine/pyrimethamine (sulfadoxine + pyrimethamine)
Antipneumocystosis and antitoxoplasmosis medicines[edit]
Pyrimethamine
Sulfadiazine
Sulfamethoxazole/trimethoprim (sulfamethoxazole + trimethoprim)
Pentamidineα
Antitrypanosomal medicines[edit]
African trypanosomiasis[edit]
Fexinidazole[note 66]
Medicines for the treatment of 1st stage African trypanosomiasis[edit]
Pentamidine[note 67]
Suramin sodium[note 68]
Medicines for the treatment of 2nd stage African trypanosomiasis[edit]
Eflornithine[note 69]
Melarsoprol
Nifurtimox[note 70]
Melarsoprolα
American trypanosomiasis[edit]
Benznidazole
Nifurtimox
Medicines for ectoparasitic infections[edit]
Ivermectin
Antimigraine medicines[edit]
For treatment of acute attack[edit]
Acetylsalicylic acid (aspirin)
Ibuprofen
Paracetamol (acetaminophen)
Sumatriptan
For prophylaxis[edit]
Propranolol
Immunomodulators and antineoplastics[edit]
Immunomodulators for non-malignant disease[edit]
Adalimumabα[note 71]
Azathioprineα
Ciclosporinα
Tacrolimusα
Antineoplastics and supportive medicines[edit]
Cytotoxic medicines[edit]
Arsenic trioxideα
Asparaginaseα[note 72]
Bendamustineα
Bleomycinα
Calcium folinateα
Capecitabineα
Carboplatinα
Chlorambucilα
Cisplatinα
Cyclophosphamideα
Cytarabineα
Dacarbazineα
Dactinomycinα
Daunorubicinα
Docetaxelα
Doxorubicinα
Etoposideα
Fludarabineα
Fluorouracilα
Gemcitabineα
Hydroxycarbamideα
Ifosfamideα
Irinotecanα
Melphalanα
Mercaptopurineα
Methotrexateα
Oxaliplatinα
Paclitaxelα
Pegaspargaseα[note 72]
Procarbazineα
Realgar Indigo naturalis formulationα
Tioguanineα
Vinblastineα
Vincristineα
Vinorelbineα
Targeted therapies[edit]
All-trans retinoic acid (tretinoin) (ATRA)α
Bortezomibα
Dasatinibα
Erlotinibα[note 73]
Everolimusα
Ibrutinibα
Imatinibα
Nilotinibα
Rituximabα[note 72]
Trastuzumabα[note 72]
Immunomodulators[edit]
Filgrastimα[note 72]
Lenalidomideα
Nivolumabα[note 74]
Thalidomideα
Hormones and antihormones[edit]
Abirateroneα[note 75]
Anastrozoleα[note 76]
Bicalutamideα[note 77]
Dexamethasoneα
Hydrocortisoneα
Leuprorelinα[note 78]
Methylprednisoloneα
Prednisoloneα[note 79]
Tamoxifenα
Supportive medicines[edit]
Allopurinolα
Mesnaα
Rasburicaseα
Zoledronic acidα
Antiparkinsonism medicines[edit]
Biperiden[note 80]
Levodopa/carbidopa (levodopa + carbidopa)[note 81]
Medicines affecting the blood[edit]
Antianaemia medicines[edit]
Ferrous salt
Ferrous salt/folic acid (ferrous salt + folic acid)
Folic acid[note 82]
Hydroxocobalamin
Erythropoiesis-stimulating agentsα[note 83]
Medicines affecting coagulation[edit]
Dabigatran[note 84]
Enoxaparin[note 85]
Heparin sodium
Phytomenadione
Protamine sulfate
Tranexamic acid
Warfarin
Desmopressinα
Heparin sodiumα
Protamine sulfateα
Warfarinα
Other medicines for haemoglobinopathies[edit]
Deferoxamineα[note 86]
Hydroxycarbamideα
Blood products of human origin and plasma substitutes[edit]
Blood and blood components[edit]
  Bag containing one unit of fresh frozen plasma
Fresh frozen plasma
Platelets
Red blood cells
Whole blood
Plasma-derived medicines[edit]
Human immunoglobulins[edit]
Rho(D) immune globulin (anti-D immunoglobulin)
Anti-rabies immunoglobulin
Anti-tetanus immunoglobulin
Normal immunoglobulinα
Blood coagulation factors[edit]
Coagulation factor VIIIα
Coagulation factor IXα
Plasma substitutes[edit]
Dextran 70[note 87]
Cardiovascular medicines[edit]
Antianginal medicines[edit]
Bisoprolol[note 88]
Glyceryl trinitrate
Isosorbide dinitrate
Verapamil
Antiarrhythmic medicines[edit]
Bisoprolol[note 88]
Digoxin
Epinephrine (adrenaline)
Lidocaine
Verapamil
Amiodaroneα
Antihypertensive medicines[edit]
Amlodipine[note 89]
Bisoprolol[note 90]
Enalapril[note 91]
Hydralazine[note 92]
Hydrochlorothiazide[note 93]
Lisinopril/amlodipine (lisinopril + amlodipine)[note 94]
Lisinopril/hydrochlorothiazide (lisinopril + hydrochlorothiazide)[note 95]
Losartan[note 96]
Methyldopa[note 97]
Telmisartan/amlodipine (telmisartan + amlodipine)[note 98]
Telmisartan/hydrochlorothiazide (telmisartan + hydrochlorothiazide)[note 99]
Sodium nitroprussideα
Medicines used in heart failure[edit]
Bisoprolol[note 88]
Digoxin
Enalapril[note 100]
Furosemide[note 101]
Hydrochlorothiazide[note 93]
Losartan[note 96]
Spironolactone
Dopamineα
Antithrombotic medicines[edit]
Anti-platelet medicines[edit]
Acetylsalicylic acid (aspirin)
Clopidogrel
Thrombolytic medicines[edit]
Alteplaseα
Streptokinaseα
Lipid-lowering agents[edit]
Simvastatin[note 102]
Dermatological medicines (topical)[edit]
Antifungal medicines[edit]
Miconazole[note 103]
Selenium sulfide
Sodium thiosulfate
Terbinafine
Anti-infective medicines[edit]
Mupirocin
Potassium permanganate
Silver sulfadiazine
Anti-inflammatory and antipruritic medicines[edit]
Betamethasone[note 104]
Calamine
Hydrocortisone[note 105]
Medicines affecting skin differentiation and proliferation[edit]
Benzoyl peroxide
Calcipotriol[note 106]
Coal tar
Fluorouracil
Podophyllum resin[note 107]
Salicylic acid
Urea
Scabicides and pediculicides[edit]
Benzyl benzoate[note 108]
Permethrin
Diagnostic agents[edit]
Ophthalmic medicines[edit]
Fluorescein
Tropicamide[note 109]
Radiocontrast media[edit]
Amidotrizoate
Barium sulfate
Iohexol
Barium sulfateα
Meglumine iotroxateα
Antiseptics and disinfectants[edit]
Antiseptics[edit]
Chlorhexidine
Ethanol[note 110]
Povidone iodine[note 111]
Disinfectants[edit]
Alcohol based hand rub
Chlorine base compound
Chloroxylenol[note 112]
Glutaral
Diuretics[edit]
Amiloride
Furosemide[note 113]
Hydrochlorothiazide[note 93]
Mannitol
Spironolactone
Hydrochlorothiazideα[note 114]
Mannitolα
Spironolactoneα
Gastrointestinal medicines[edit]
Pancreatic enzymesα
Antiulcer medicines[edit]
Omeprazole[note 115]
Ranitidine[note 116]
Antiemetic medicines[edit]
Dexamethasone
Metoclopramide
Ondansetron[note 9]
Aprepitantα
Anti-inflammatory medicines[edit]
Sulfasalazine[note 117]
Hydrocortisoneα
Prednisoloneα
Laxatives[edit]
Senna[note 118]
Medicines used in diarrhoea[edit]
Oral rehydration salts + zinc sulfate (Co-packaged)
Oral rehydration[edit]
Oral rehydration salts
Medicines for diarrhea[edit]
Zinc sulfate[note 119]
Medicines for endocrine disorders[edit]
Adrenal hormones and synthetic substitutes[edit]
Fludrocortisone
Hydrocortisone
Androgens[edit]
Testosteroneα
Estrogens[edit]
No listings in this section.

Progestogens[edit]
Medroxyprogesterone acetate[note 120]
Medicines for diabetes[edit]
Insulins[edit]
Insulin injection (soluble)[note 72]
Intermediate-acting insulin[note 72]
Long-acting insulin analogues[note 121]
Oral hypoglycaemic agents[edit]
Empagliflozin[note 122]
Gliclazide[note 123]
Metformin
Metforminα
Medicines for hypoglycaemia[edit]
Glucagon
Diazoxideα
Thyroid hormones and antithyroid medicines[edit]
Levothyroxine
Potassium iodide
Methimazole[note 124]
Propylthiouracil[note 125]
Lugol's solutionα
Methimazoleα[note 124]
Potassium iodideα
Propylthiouracilα[note 126]
Immunologicals[edit]
Diagnostic agents[edit]
Tuberculin, purified protein derivative (PPD)
Sera, immunoglobulins and monoclonal antibodies[edit]
Anti-rabies virus monoclonal antibodies[note 72]
Antivenom immunoglobulin[note 127]
Diphtheria antitoxin
Equine rabies immunoglobulin
Vaccines[edit]
  A vial of oral cholera vaccine
Recommendations for all

BCG vaccine
Diphtheria vaccine
Haemophilus influenzae type b vaccine
Hepatitis B vaccine
Human papilloma virus (HPV) vaccine
Measles vaccine
Pertussis vaccine
Pneumococcal vaccine
Poliomyelitis vaccine
Rotavirus vaccine
Rubella vaccine
Tetanus vaccine
Recommendations for certain regions

Japanese encephalitis vaccine[note 128]
Tick-borne encephalitis vaccine[note 128]
Yellow fever vaccine[note 128]
Recommendations for some high-risk populations

Cholera vaccine[note 129]
Dengue vaccine[note 129]
Hepatitis A vaccine[note 129]
Meningococcal meningitis vaccine[note 129]
Rabies vaccine[note 129]
Typhoid vaccine[note 129]
Recommendations for immunization programmes with certain characteristics

Influenza vaccine (seasonal)[note 130]
Mumps vaccine[note 130]
Varicella vaccine[note 130]
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors[edit]
Atracurium
Neostigmine
Suxamethonium
Vecuronium
Pyridostigmineα
Vecuroniumα
Ophthalmological preparations[edit]
Anti-infective agents[edit]
Aciclovir
Azithromycin
Erythromycin[note 131]
Gentamicin[note 132]
Natamycin
Ofloxacin[note 133]
Tetracycline[note 134]
Anti-inflammatory agents[edit]
Prednisolone
Local anesthetics[edit]
Tetracaine[note 135]
Miotics and antiglaucoma medicines[edit]
Acetazolamide
Latanoprost
Pilocarpine[note 136]
Timolol[note 137]
Mydriatics[edit]
Atropine[note 138]
Epinephrine (adrenaline)α
Anti-vascular endothelial growth factor (VEGF)[edit]
Bevacizumabα[note 72]
Medicines for reproductive health and perinatal care[edit]
Contraceptives[edit]
Oral hormonal contraceptives[edit]
Ethinylestradiol/levonorgestrel (ethinylestradiol + levonorgestrel)
Ethinylestradiol/norethisterone (ethinylestradiol + norethisterone)
Levonorgestrel
Ulipristal
Injectable hormonal contraceptives[edit]
Estradiol cypionate/medroxyprogesterone acetate (estradiol cypionate + medroxyprogesterone acetate)
Medroxyprogesterone acetate
Norethisterone enantate
Intrauterine devices[edit]
IUD with copper
IUD with progestogen
Barrier methods[edit]
Condoms
Diaphragms
Implantable contraceptives[edit]
Etonogestrel-releasing implant
Levonorgestrel-releasing implant
Intravaginal contraceptives[edit]
Ethinylestradiol/etonogestrel (ethinylestradiol + etonogestrel)
Progesterone vaginal ring[note 139]
Ovulation inducers[edit]
Clomifeneα
Uterotonics[edit]
Carbetocin
Ergometrine[note 140]
Mifepristone + misoprostol (Co-packaged)[note 141]
Misoprostol[note 142]
Oxytocin
Antioxytocics (tocolytics)[edit]
Nifedipine
Medicines administered to the mother[edit]
Dexamethasone
Multiple micronutrient supplement
Tranexamic acid
Medicines administered to the neonate[edit]
Caffeine citrate
Chlorhexidine
Ibuprofenα[note 143]
Prostaglandin E1α[note 144]
Surfactantα
Peritoneal dialysis solution[edit]
Intraperitoneal dialysis solution (of appropriate composition)α
Medicines for mental and behavioural disorders[edit]
Medicines used in psychotic disorders[edit]
Chlorpromazine
Fluphenazine
Haloperidol
Paliperidone[note 145]
Risperidone
Chlorpromazineα
Clozapineα
Haloperidolα
Medicines used in mood disorders[edit]
Medicines used in depressive disorders[edit]
Amitriptyline
Fluoxetine[note 146]
Fluoxetineα
Medicines used in bipolar disorders[edit]
Carbamazepine
Lithium carbonate
Valproic acid (sodium valproate)[note 18]
Medicines for anxiety disorders[edit]
Diazepam
Medicines used for obsessive compulsive disorders[edit]
Clomipramine
Medicines for disorders due to psychoactive substance use[edit]
Bupropion
Nicotine replacement therapy
Varenicline
Methadoneα[note 147]
Medicines acting on the respiratory tract[edit]
Antiasthmatics and medicines for chronic obstructive pulmonary disease[edit]
Budesonide[note 148]
Budesonide/formoterol (budesonide + formoterol)[note 149]
Epinephrine (adrenaline)
Ipratropium bromide
Salbutamol[note 150]
Tiotropium[note 151]
Solutions correcting water, electrolyte and acid-base disturbances[edit]
Oral[edit]
Oral rehydration salts
Potassium chloride
Parenteral[edit]
Glucose
Glucose with sodium chloride
Potassium chloride
Sodium chloride
Sodium hydrogen carbonate
Sodium lactate, compound solution
Miscellaneous[edit]
Water for injection
Vitamins and minerals[edit]
Ascorbic acid
Calcium
Colecalciferol[note 152]
Ergocalciferol[note 153]
Iodine
Multiple micronutrient powder
Nicotinamide
Pyridoxine
Retinol
Riboflavin
Thiamine
Calcium gluconateα
Ear, nose and throat medicines[edit]
Acetic acid
Budesonide
Ciprofloxacin[note 154]
Xylometazoline
Medicines for diseases of joints[edit]
Medicines used to treat gout[edit]
Allopurinol
Disease-modifying agents used in rheumatoid disorders (DMARDs)[edit]
Chloroquine
Azathioprineα
Hydroxychloroquineα
Methotrexateα
Penicillamineα
Sulfasalazineα
Juvenile joint diseases[edit]
Acetylsalicylic acid (aspirin)[note 155]
Dental preparations[edit]
Fluoride
Glass ionomer cement
Silver diamine fluoride
Notes[edit]
An α indicates the medicine is only on the complementary list. For these items specialized diagnostic or monitoring or specialist training are needed. An item may also be listed as complementary on the basis of higher costs or a less attractive cost-benefit ratio.[4][14]

.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ Thiopental may be used as an alternative depending on local availability and cost.

^ (For use in spinal anaesthesia during delivery, to prevent hypotension).

^ No more than 30% oxygen should be used to initiate resuscitation of neonates less than or equal to 32 weeks of gestation.

^ Not in children less than 3 months.

^ Not recommended for anti‐inflammatory use due to lack of proven benefit to that effect.

^ For the management of cancer pain

^ Alternatives limited to hydromorphone and oxycodone

^ For the management of cancer pain.

^ Jump up to: a b Alternatives limited to dolasetron, granisetron, palonosetron, and tropisetron

^ Alternatives limited to cetirizine and fexofenadine

^ There may be a role for sedating antihistamines for limited indications (EMLc).

^ Alternatives limited to prednisone

^ For use as adjunctive therapy for treatment-resistant partial or generalized seizures.

^ Alternatives limited to diazepam and midazolam

^ For use in eclampsia and severe pre‐eclampsia and not for other convulsant disorders.

^ For buccal administration when solution for oromucosal administration is not available.

^ The presence of both 25 mg/5 mL and 30 mg/5 mL strengths on the same market would cause confusion in prescribing and dispensing and should be avoided.

^ Jump up to: a b Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.

^ Oxamniquine is listed for use when praziquantel treatment fails.

^ > 1 month.

^ Only for the presumptive treatment of epidemic meningitis in children older than two years and in adults.

^ Alternatives limited to 4th level ATC chemical subgroup (J01CF Beta-lactamase resistant penicillins)

^ cloxacillin, dicloxacillin and flucloxacillin are preferred for oral administration due to better bioavailability.

^ Use in children <8 years only for life-threatening infections when no alternative exists.

^ Procaine benzylpenicillin is not recommended as first-line treatment for neonatal sepsis except in settings with high neonatal mortality, when given by trained health workers in cases where hospital care is not achievable.

^ Third-generation cephalosporin of choice for use in hospitalized neonates.

^ Do not administer with calcium and avoid in infants with hyperbilirubinemia.

^ > 41 weeks corrected gestational age.

^ Erythromycin may be an alternative. For use in combination regimens for eradication of H. pylori in adults

^ Imipenem/cilastatin is an alternative for complicated intraabdominal infections and high-risk febrile neutropenia only, except for acute bacterial meningitis in neonates, where meropenem is preferred

^ For use only in patients with HIV receiving protease inhibitors

^ For use only in combination with meropenem or imipenem/cilastatin

^ ≥ 5 years

^ Terizidone may be an alternative

^ Prothionamide may be an alternative

^ Imipenem/cilastatin may be an alternative

^ For treatment of chronic pulmonary aspergillosis, histoplasmosis, sporotrichosis, paracoccidioidomycosis, mycoses caused by Talaromyces marneffei and chromoblastomycosis; and prophylaxis of histoplasmosis and infections caused by T. marneffei in AIDS patients.

^ For treatment of chronic pulmonary aspergillosis and acute invasive aspergillosis.

^ Alternatives limited to anidulafungin and caspofungin

^ Alternatives limited to valaciclovir

^ also indicated for pre-exposure prophylaxis.

^ For use in pregnant women and in second-line regimens in accordance with WHO treatment guidelines.

^ Jump up to: a b Alternatives limited to lamivudine (for emtricitabine)

^ combination also indicated for pre-exposure prophylaxis

^ For the treatment of viral haemorrhagic fevers

^ For the treatment of cytomegalovirus retinitis (CMVr).

^ For severe illness due to confirmed or suspected influenza virus infection in critically ill hospitalized patients

^ For the treatment of cytomegalovirus retinitis (CMVr).

^ Pangenotypic when used in combination with sofosbuvir

^ Pangenotypic when used in combination with daclatasvir

^ For the treatment of hepatitis C, in combination with direct acting anti-viral medicines

^ To be used in combination with ribavirin

^ Alternatives limited to tinidazole

^ Jump up to: a b To be used in combination with artesunate 50 mg.

^ For use in the management of severe malaria.

^ Not recommended in the first trimester of pregnancy or in children below 5 kg.

^ To be used in combination with either amodiaquine, mefloquine or sulfadoxine + pyrimethamine.

^ Other combinations that deliver the target doses required such as 153 mg or 200 mg (as hydrochloride) with 50 mg artesunate can be alternatives.

^ For use only for the treatment of Plasmodium vivax infection.

^ For use only in combination with quinine.

^ Only for use to achieve radical cure of Plasmodium vivax and Plasmodium ovale infections, given for 14 days.

^ For use only in the management of severe malaria, and should be used in combination with doxycycline.

^ Only in combination with artesunate 50 mg.

^ For use only in Central American regions, for Plasmodium vivax infections.

^ For use only in combination with chloroquine.

^ For the treatment of 1st and 2nd stage human African trypanosomiasis due to Trypanosoma brucei gambiense infection.

^ To be used for the treatment of Trypanosoma brucei gambiense infection.

^ To be used for the treatment of the initial phase of Trypanosoma brucei rhodesiense infection.

^ To be used for the treatment of Trypanosoma brucei gambiense infection

^ Only to be used in combination with eflornithine, for the treatment of Trypanosoma brucei gambiense infection.

^ Certolizumab pegol, etanercept, golimumab and infliximab are alternatives, including quality-assured biosimilars

^ Jump up to: a b c d e f g h i Including quality-assured biosimilars

^ Afatinib and gefitinib are alternatives

^ Pembrolizumab is an alternative, including quality-assured biosimilars

^ Alternatives limited to enzalutamide

^ Alternatives limited to 4th level ATC chemical subgroup (L02BG Aromatase inhibitors)

^ Alternatives limited to flutamide and nilutamide

^ Alternatives limited to goserelin and triptorelin

^ Alternatives limited to prednisone

^ Alternatives limited to trihexyphenidyl

^ Alternatives limited to benserazide (for carbidopa)

^ periconceptual use for prevention of first occurrence of neural tube defects

^ Alternatives limited to epoetin alfa, beta and theta, darbepoetin alfa, methoxy polyethylene glycol-epoetin beta, and their quality-assured biosimilars.

^ Apixaban, edoxaban and rivaroxaban are alternatives

^ Alternatives are limited to dalteparin and nadroparin, including their quality-assured biosimilars.

^ Alternatives are limited to the oral form of deferasirox.

^ Polygeline, injectable solution, 3.5% is considered an alternative.

^ Jump up to: a b c Includes carvedilol and metoprolol as alternatives

^ Alternatives limited to 4th level ATC chemical subgroup (C08CA Dihydropyridine derivatives)

^ Includes atenolol, carvedilol, and metoprolol as alternatives. Atenolol should not be used as a first-line agent in uncomplicated hypertension in patients > 60 years.

^ Alternatives limited to 4th level ATC chemical subgroup (C09AA ACE inhibitors, plain)

^ Hydralazine is listed for use in the acute management of severe pregnancy‐induced hypertension only. Its use in the treatment of essential hypertension is not recommended in view of the availability of more evidence of efficacy and safety of other medicines.

^ Jump up to: a b c Alternatives limited to chlorothiazide, chlorthalidone, and indapamide

^ Alternatives limited to 4th level ATC chemical subgroup (C09AA ACE inhibitors, plain) (for lisinopril) and 4th level ATC chemical subgroup (C08CA Dihydropyridine derivatives) (for amlodipine)

^ Alternatives limited to 4th level ATC chemical subgroup (C09AA ACE inhibitors, plain) (for lisinopril) and chlorthalidone, chlorothiazide, indapamide (for hydrochlorothiazide)

^ Jump up to: a b Alternatives limited to 4th level ATC chemical subgroup (C09CA Angiotensin II receptor blockers (ARBs), plain)

^ Methyldopa is listed for use only in the management of pregnancy-induced hypertension. Its use in the treatment of essential hypertension is not recommended in view of the evidence of greater efficacy and safety of other medicines.

^ Alternatives limited to 4th level ATC chemical subgroup (C09CA Angiotensin II receptor blockers (ARBs), plain) (for telmisartan) and 4th level ATC chemical subgroup (C08CA Dihydropyridine derivatives) (for amlodipine)

^ Alternatives limited to 4th level ATC chemical subgroup (C09CA Angiotensin II receptor blockers (ARBs), plain) (for telmisartan) and chlorthalidone, chlorothiazide, indapamide (for hydrochlorothiazide)

^ Alternatives limited to 4th level ATC chemical subgroup (C09AA ACE inhibitors, plain)

^ Alternatives limited to bumetanide and torasemide

^ For use in high‐risk patients. Alternatives limited to atorvastatin, fluvastatin, lovastatin, and pravastatin

^ Alternatives limited to 4th level ATC chemical subgroup (D01AC Imidazole and triazole derivatives) excluding combinations

^ Alternatives limited to 4th level ATC chemical subgroup (D07AC Corticosteroids, potent (group III))

^ Alternatives limited to 4th level ATC chemical subgroup (D07AA Corticosteroids, weak (group I))

^ Alternatives limited to calcitriol and tacalcitol

^ Alternatives limited to podophyllotoxin

^ Alternatives limited to precipitated sulfur topical ointment

^ Alternatives limited to atropine and cyclopentolate

^ Alternatives limited to propanol

^ Alternatives limited to iodine

^ Alternatives limited to 4th level ATC chemical subgroup (D08AE Phenol and derivatives)

^ Alternatives limited to bumetanide and torasemide

^ Alternatives limited to chlorothiazide and chlorthalidone

^ Alternatives limited to 4th level ATC chemical subgroup (A02BC Proton pump inhibitors) excluding combinations

^ Alternatives limited to 4th level ATC chemical subgroup (A02BA H2-receptor antagonists) excluding combinations

^ Alternatives limited to mesalazine

^ Alternatives limited to bisacodyl

^ In acute diarrhoea zinc sulfate should be used as an adjunct to oral rehydration salts.

^ Alternatives limited to norethisterone

^ Alternatives limited to insulin degludec, insulin detemir, and insulin glargine, including quality-assured biosimilars

^ Alternatives limited to canagliflozin and dapagliflozin

^ Glibenclamide not suitable above 60 years. Alternatives limited to 4th level ATC chemical subgroup (A10BB Sulfonylureas)

^ Jump up to: a b Carbimazole is an alternative depending on local availability

^ For use when alternative first-line treatment is not appropriate or available; and in patients during the first trimester of pregnancy.

^ For use when alternative first-line treatment is not appropriate or available

^ Exact type to be defined locally

^ Jump up to: a b c Recommended for certain regions

^ Jump up to: a b c d e f Recommended for some high-risk populations

^ Jump up to: a b c Recommended only for immunization programmes with certain characteristics

^ For infections due to Chlamydia trachomatis or Neisseria gonorrhoeae.

^ Alternatives limited to amikacin, kanamycin, netilmicin, and tobramycin

^ Alternatives limited to 4th level ATC chemical subgroup (S01AE Fluoroquinolones)

^ Alternatives limited to chlortetracycline and oxytetracycline

^ Alternatives limited to 4th level ATC chemical subgroup (S01HA Local anaesthetics) excluding cocaine and combinations

^ Alternatives limited to carbachol

^ Alternatives limited to 4th level ATC chemical subgroup (S01ED Beta blocking agents) excluding combinations

^ Alternatives limited to cyclopentolate hydrochloride or homatropine hydrobromide only for the EMLc

^ For use in women actively breastfeeding at least 4 times per day

^ Alternatives limited to methylergometrine

^ Where permitted under national law and where culturally acceptable.

^ Only for use for induction of labour where appropriate facilities are available.

^ Alternatives limited to indometacin

^ Alternatives limited to prostaglandin E2

^ Alternatives limited to risperidone injection

^ Alternatives limited to citalopram, escitalopram, fluvoxamine, paroxetine, and sertraline

^ Alternatives limited to buprenorphine. The medicines should only be used within an established support programme.

^ Alternatives limited to beclometasone, ciclesonide, flunisolide, fluticasone, and mometasone

^ Alternatives limited to beclometasone/formoterol, budesonide/salmeterol, fluticasone/formoterol, fluticasone furoate/vilanterol, and mometasone/formoterol

^ Alternatives limited to terbutaline

^ Alternatives limited to aclidinium, glycopyrronium, and umeclidinium

^ Ergocalciferol can be used as an alternative.

^ Colecalciferol can be used as an alternative.

^ Alternatives limited to ofloxacin

^ For use for rheumatic fever, juvenile arthritis, Kawasaki disease


References[edit]


^ Jump up to: a b .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}"The WHO Essential Medicines List (EML): 30th anniversary". World Health Organization. Archived from the original on 27 May 2014. Retrieved 26 June 2016.

^ Jump up to: a b c d "Essential medicines". World Health Organization. Archived from the original on 2 October 2008. Retrieved 19 January 2017.

^ Persaud N, Jiang M, Shaikh R, Bali A, Oronsaye E, Woods H, Drozdzal G, Rajakulasingam Y, Maraj D, Wadhawan S, Umali N, Wang R, McCall M, Aronson JK, Plüddemann A, Moja L, Magrini N, Heneghan C (June 2019). "Comparison of essential medicines lists in 137 countries". Bull. World Health Organ. 97 (6): 394–404C. doi:10.2471/BLT.18.222448. hdl:10665/325509. ISSN 0042-9686. PMC 6560372. PMID 31210677.

^ Jump up to: a b c d e f "19th WHO Model List of Essential Medicines" (PDF). World Health Organization. April 2015. p. Annex 1. Retrieved 17 January 2017.

^ Jump up to: a b Bansal D, Purohit VK (January 2013). "Accessibility and use of essential medicines in health care: Current progress and challenges in India". Journal of Pharmacology & Pharmacotherapeutics. 4 (1): 13–18. doi:10.4103/0976-500X.107642. PMC 3643337. PMID 23662019.

^ "The Selection and Use of Essential Medicines – WHO Technical Report Series, No. 920: 5. Reviews of sections of the Model List: 5.2 Review of core versus complementary listing of medicines". World Health Organization (WHO). 2003. Archived from the original on 6 March 2017. Retrieved 6 March 2017.

^ Beall R (2016). "Patents and the WHO Model List of Essential Medicines (18th Edition): Clarifying the Debate on IP and Access" (PDF). World Intellectual Property Organization (WIPO). Retrieved 3 May 2017.

^ World Health Organization (1977). The selection of essential drugs : report of a WHO expert committee [meeting held in Geneva from 17 to 21 October 1977]. Geneva: World Health Organization. hdl:10665/41272. ISBN 9241206152. Technical report series; no. 615.

^ Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA,  et al. (January 2017). "Essential medicines for universal health coverage". Lancet. 389 (10067): 403–476. doi:10.1016/S0140-6736(16)31599-9. PMC 7159295. PMID 27832874.

^ Jump up to: a b c "WHO Model Lists of Essential Medicines". World Health Organization. The current versions are the 21st WHO Essential Medicines List (EML) and the 7th WHO Essential Medicines List for Children (EMLc) updated in June 2019.

^ Prakash B, Nadig P, Nayak A (2016). "Rational Prescription for a Dermatologist". Indian Journal of Dermatology. 61 (1): 32–38. doi:10.4103/0019-5154.174017. PMC 4763692. PMID 26955092.

^ Jump up to: a b World Health Organization (2017). WHO model list of essential medicines, 20th list (March 2017, amended August 2017). Geneva. hdl:10665/273826.

^ "Essential Medicines List and WHO Model Formulary". World Health Organization. Archived from the original on 3 August 2008. Retrieved 5 May 2018.

^ Jump up to: a b c d World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

^ World Health Organization (2019). Executive summary: the selection and use of essential medicines 2019: report of the 22nd WHO Expert Committee on the selection and use of essential medicines. Geneva. hdl:10665/325773. WHO/MVP/EMP/IAU/2019.05. License: CC BY-NC-SA 3.0 IGO.

^ "Strengthening access to essential medicines". World Health Organization. Retrieved 3 May 2020.

^ Jump up to: a b c d World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

^ Jump up to: a b World Health Organization (2021). Executive summary: the selection and use of essential medicines 2021: report of the 23rd WHO Expert Committee on the selection and use of essential medicines: virtual meeting, 21 June–2 July 2021. Geneva: World Health Organization. hdl:10665/345554. WHO/MHP/HPS/EML/2021.01.

^ World Health Organization (2019). World Health Organization model list of essential medicines for children: 7th list 2019. Geneva. hdl:10665/325772. WHO/MVP/EMP/IAU/2019.07. License: CC BY-NC-SA 3.0 IGO.

^ World Health Organization (2021). World Health Organization model list of essential medicines for children: 8th list (2021). Geneva: World Health Organization. hdl:10665/345534. WHO/MHP/HPS/EML/2021.03.

^ Rose K, Anker JN (2010). Guide to Paediatric Drug Development and Clinical Research. Karger Medical and Scientific Publishers. p. 42. ISBN 9783805593625.

^ Seyberth HW, Rane A, Schwab M (2011). Pediatric Clinical Pharmacology. Springer Science & Business Media. p. 358. ISBN 9783642201950.

^ Hoppu K (June 2017). "Essential Medicines for Children". Clinical Pharmacology and Therapeutics. 101 (6): 718–720. doi:10.1002/cpt.661. PMID 28182281. S2CID 23873145.


Further reading[edit]
Serafini M, Cargnin S, Massarotti A, Pirali T, Genazzani AA (September 2020). "Essential Medicinal Chemistry of Essential Medicines". Journal of Medicinal Chemistry. 63 (18): 10170–10187. doi:10.1021/acs.jmedchem.0c00415. PMC 8007110. PMID 32352778.
World Health Organization (2009).  Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. hdl:10665/44053. ISBN 9789241547659.
World Health Organization (2015). The selection and use of essential medicines. Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl:10665/189763. ISBN 9789240694941. ISSN 0512-3054. WHO technical report series; no. 994.
World Health Organization (2017). The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl:10665/259481. ISBN 978-92-4-121015-7. ISSN 0512-3054. WHO technical report series; no. 1006.
World Health Organization (2019). The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl:10665/330668. ISBN 9789241210300. ISSN 0512-3054. WHO technical report series;1021.
World Health Organization (2019). "Additions and deletions of medicines on the WHO model lists of essential medicines: 1977–2017". hdl:10665/278038. WHO/MVP/EMP/IAU/2019.01. License: CC BY-NC-SA 3.0 IGO. {{cite journal}}: Cite journal requires |journal= (help)
External links[edit]
eEML - Electronic Essential Medicines List

.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;justify-content:center;align-items:baseline}.mw-parser-output .portal-bar-bordered{padding:0 2em;background-color:#fdfdfd;border:1px solid #a2a9b1;clear:both;margin:1em auto 0}.mw-parser-output .portal-bar-unbordered{padding:0 1.7em;margin-left:0}.mw-parser-output .portal-bar-header{margin:0 1em 0 0.5em;padding:0.2em 0;flex:0 0 auto;min-height:24px;line-height:22px}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0 1 auto;padding:0.15em 0;column-gap:1em}.mw-parser-output .portal-bar-item{display:flex;align-items:baseline;margin:0.15em 0;min-height:24px;text-align:left}.mw-parser-output .portal-bar-logo{width:22px;line-height:22px;margin:0 0.2em;text-align:right}.mw-parser-output .portal-bar-link{margin:0 0.2em;text-align:left}@media screen and (max-width:768px){.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;flex-flow:column wrap}.mw-parser-output .portal-bar-header{text-align:center;flex:0;padding-left:0.5em;margin:0 auto}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0;margin:0 auto;column-gap:1em;border-top:1px solid #a2a9b1}}.mw-parser-output .navbox+link+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .navbox+style+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .portal-bar+.navbox-styles+.navbox{margin-top:-1px}Portals:PoliticsMedicineViruses





